Valuation: Cosmos Holdings Inc.

Market Cap 27.93M 25.01M 23.01M 20.84M 38.96M 2.65B 39.69M 274M 110M 1.39B 105M 103M 4.4B P/E 2026 *
-1.85x
P/E 2027 * 3.96x
Enterprise Value 27.93M 25.01M 23.01M 20.84M 38.96M 2.65B 39.69M 274M 110M 1.39B 105M 103M 4.4B EV / Sales 2026 *
0.33x
EV / Sales 2027 * 0.22x
Free-Float
74.12%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 25/02/2016
Director of Finance/CFO 43 10/11/2020
Chief Operating Officer 56 31/01/2023
Director TitleAgeSince
Director/Board Member 58 12/01/2014
Chairman 60 25/02/2016
Director/Board Member 59 17/11/2016
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 27.93M
+3.24%+11.45%+68.06%+150.88% 1,224B
-0.25%+4.14%+45.32%+86.86% 662B
+1.22%+3.12%+29.08%+107.59% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+2.34%+3.24%+73.82%+46.06% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+1.33%+6.10%+59.61%+77.08% 249B
+3.56%+9.72%+44.55%+120.14% 205B
Average +1.49%+2.59%+46.79%+83.39% 464.09B
Weighted average by Cap. +2.13%+3.04%+51.15%+98.52%

Financials

2026 *2027 *
Net sales 85.41M 76.49M 70.36M 63.75M 119M 8.11B 121M 839M 337M 4.27B 321M 314M 13.45B 130M 116M 107M 96.74M 181M 12.31B 184M 1.27B 511M 6.47B 486M 476M 20.41B
Net income 5.97M 5.34M 4.91M 4.45M 8.32M 566M 8.48M 58.61M 23.53M 298M 22.39M 21.91M 940M 8.81M 7.89M 7.26M 6.58M 12.3M 837M 12.53M 86.57M 34.75M 440M 33.07M 32.37M 1.39B
Net Debt - -
Projected Income Statement - Annual - Cosmos Holdings Inc.
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cosmos Holdings Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2775USD
Average target price
2.950USD
Spread / Average Target
+963.06%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cosmos Holdings Inc.